Mutation of the androgen receptor causes oncogenic transformation of the prostate.

Recent evidence demonstrates that the androgen receptor (AR) continues to influence prostate cancer growth despite medical therapies that reduce circulating androgen ligands to castrate levels and/or block ligand binding. Whereas the mutation, amplification, overexpression of AR, or cross-talk between AR and other growth factor pathways may explain the failure of androgen ablation therapies in some cases, there is little evidence supporting a causal role between AR and prostate cancer. In this study, we functionally and directly address the role whereby AR contributes to spontaneous cancer progression by generating transgenic mice expressing (i) AR-WT to recapitulate increased AR levels and ligand sensitivity, (ii) AR-T857A to represent a promiscuous AR ligand response, and (iii) AR-E231G to model altered AR function. Whereas transgenes encoding either AR-WT or AR-T857A did not cause prostate cancer when expressed at equivalent levels, expression of AR-E231G, which carries a mutation in the most highly conserved signature motif of the NH2-terminal domain that also influences interactions with cellular coregulators, caused rapid development of prostatic intraepithelial neoplasia that progressed to invasive and metastatic disease in 100% of mice examined. Taken together, our data now demonstrate the oncogenic potential of steroid receptors and implicate altered AR function and receptor coregulator interaction as critical determinants of prostate cancer initiation, invasion, and metastasis.

[1]  S. Yeh,et al.  From HER2/Neu signal cascade to androgen receptor and its coactivators: a novel pathway by induction of androgen target genes through MAP kinase in prostate cancer cells. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[2]  Howard M. Einspahr,et al.  Crystallographic structures of the ligand-binding domains of the androgen receptor and its T877A mutant complexed with the natural agonist dihydrotestosterone , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[3]  E. Small,et al.  Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist. , 1999, Cancer research.

[4]  R. Hodges,et al.  Positional dependence of the effects of negatively charged Glu side chains on the stability of two‐stranded α‐helical coiled‐coils , 1997, Journal of peptide science : an official publication of the European Peptide Society.

[5]  N. Greenberg,et al.  Immunization Against Luteinizing Hormone-Releasing Hormone Fusion Proteins Does Not Decrease Prostate Cancer in the Transgenic Adenocarcinoma Mouse Prostate Model , 2003, Experimental biology and medicine.

[6]  I. McEwan,et al.  Role of conserved hydrophobic amino acids in androgen receptor AF-1 function. , 2003, Journal of molecular endocrinology.

[7]  W. Gerald,et al.  Targeting the androgen receptor: improving outcomes for castration-resistant prostate cancer. , 2004, Endocrine-related cancer.

[8]  Jian Hui Wu,et al.  The androgen receptor gene mutations database (ARDB): 2004 update , 2004, Human mutation.

[9]  R. Matusik,et al.  Prostate cancer in a transgenic mouse. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[10]  R. Vessella,et al.  Molecular determinants of resistance to antiandrogen therapy , 2004, Nature Medicine.

[11]  G. Jenster,et al.  The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens , 1992, Journal of Steroid Biochemistry and Molecular Biology.

[12]  A. Ruffion,et al.  Inhibition of growth and induction of apoptosis by androgens of a variant of LNCaP cell line , 2000, The Journal of Steroid Biochemistry and Molecular Biology.

[13]  Division of Surgery. , 1995 .

[14]  Bruce M. Spiegelman,et al.  Biological Control through Regulated Transcriptional Coactivators , 2004, Cell.

[15]  M. Rubin,et al.  Prostate Pathology of Genetically Engineered Mice: Definitions and Classification. The Consensus Report from the Bar Harbor Meeting of the Mouse Models of Human Cancer Consortium Prostate Pathology Committee , 2004, Cancer Research.

[16]  T. Visakorpi,et al.  Androgen receptor gene and hormonal therapy failure of prostate cancer. , 1998, The American journal of pathology.

[17]  E. Wilson,et al.  An Androgen Receptor NH2-terminal Conserved Motif Interacts with the COOH Terminus of the Hsp70-interacting Protein (CHIP)* , 2004, Journal of Biological Chemistry.

[18]  M. Vihinen,et al.  Pattern of Somatic Androgen Receptor Gene Mutations in Patients with Hormone-Refractory Prostate Cancer , 2002, Laboratory Investigation.

[19]  A. Amorosi,et al.  Estimation of Prostate Cancer Volume by Endorectal Coil Magnetic Resonance Imaging vs. Pathologic Volume , 1999, European Urology.

[20]  J Isola,et al.  Androgen receptor gene amplification: a possible molecular mechanism for androgen deprivation therapy failure in prostate cancer. , 1997, Cancer research.

[21]  H. Scher,et al.  Collocation of androgen receptor gene mutations in prostate cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[22]  B. Foster,et al.  Characterization of the FGF axis and identification of a novel FGFR1iiic isoform during prostate cancer progression in the TRAMP model , 1999, Prostate Cancer and Prostatic Diseases.

[23]  R. Matusik,et al.  The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice. , 1994, Molecular endocrinology.

[24]  N. Greenberg,et al.  Steroid hormones, polypeptide growth factors, hormone refractory prostate cancer, and the neuroendocrine phenotype , 2004, Journal of cellular biochemistry.

[25]  N. C. Price,et al.  Conformational Analysis of the Androgen Receptor Amino-terminal Domain Involved in Transactivation , 2002, The Journal of Biological Chemistry.

[26]  J. Thompson,et al.  CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties and weight matrix choice. , 1994, Nucleic acids research.

[27]  H. Scher,et al.  Prostate cancer: a dynamic illness with shifting targets. , 2003, The Lancet. Oncology.

[28]  B. Foster,et al.  Enforced expression of FGF-7 promotes epithelial hyperplasia whereas a dominant negative FGFR2iiib promotes the emergence of neuroendocrine phenotype in prostate glands of transgenic mice. , 2002, Differentiation; research in biological diversity.

[29]  M. Gleave,et al.  Intermittent androgen suppression for prostate cancer: rationale and clinical experience , 1998, Prostate Cancer and Prostatic Diseases.

[30]  B. Foster,et al.  Hormone Status Selects for Spontaneous Somatic Androgen Receptor Variants That Demonstrate Specific Ligand and Cofactor Dependent Activities in Autochthonous Prostate Cancer* , 2001, The Journal of Biological Chemistry.

[31]  C. Huggins,et al.  STUDIES ON PROSTATIC CANCER: II. THE EFFECTS OF CASTRATION ON ADVANCED CARCINOMA OF THE PROSTATE GLAND , 1941 .

[32]  D. Peehl,et al.  Two mutations identified in the androgen receptor of the new human prostate cancer cell line MDA PCa 2a. , 1999, The Journal of urology.

[33]  D. Feldman,et al.  The development of androgen-independent prostate cancer , 2001, Nature Reviews Cancer.

[34]  Michael M Lieber,et al.  Journal Review , 2003, International Society of Hair Restoration Surgery.

[35]  K. Makino,et al.  HER-2/neu promotes androgen-independent survival and growth of prostate cancer cells through the Akt pathway. , 2000, Cancer research.

[36]  Tsuey-Ming Chen,et al.  Pathobiology of autochthonous prostate cancer in a pre‐clinical transgenic mouse model , 2003, The Prostate.

[37]  Peter Scholz,et al.  Structural Evidence for Ligand Specificity in the Binding Domain of the Human Androgen Receptor , 2000, The Journal of Biological Chemistry.

[38]  J. Isaacs,et al.  A history of prostate cancer treatment , 2002, Nature Reviews Cancer.

[39]  F. S. French,et al.  A mechanism for androgen receptor-mediated prostate cancer recurrence after androgen deprivation therapy. , 2001, Cancer research.

[40]  G. Buchanan,et al.  Mutations in the androgen receptor gene are associated with progression of human prostate cancer to androgen independence. , 1996, Clinical cancer research : an official journal of the American Association for Cancer Research.

[41]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[42]  H. Klocker,et al.  Androgen receptor activation in prostatic tumor cell lines by insulin-like growth factor-I, keratinocyte growth factor and epidermal growth factor. , 1995, European urology.